# VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

> **NCT05374538** · PHASE1 · TERMINATED · sponsor: **Vitrac Therapeutics, LLC** · enrollment: 3 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** VIC-1911
- **DRUG:** sotorasib

## Key facts

- **NCT ID:** NCT05374538
- **Lead sponsor:** Vitrac Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-09
- **Primary completion:** 2023-08-26
- **Final completion:** 2023-08-26
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05374538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05374538, "VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05374538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*